Skip to content

H.R. 1843 · 119th Congress (2025–2027)

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is H.R. 1843’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

Sponsor
Rep. Neal P. Dunn (R-FL-2)
Cosponsors
1 cosponsor

1 original · 0 later

  1. Rep. Kevin Mullin (D-CA-15)· Original · Mar 5, 2025
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest

    Referred to committee

    Referred to the House Committee on Energy and Commerce.

    Sources

Committees

  1. HouseEnergy and CommerceReferred Mar 5, 2025
    1. Sep 17, 2025 · Markup

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (1)
  1. To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

    Official title, Display title · Introduced in House